Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.61 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744600 | 1.00 | CHRM1 (0.61) | CHRM1CHRM2CACNA1IKCNH2CHRM3 | |
| SCHEMBL26430720 | 0.95 | CHRM1 (0.55) | CHRM1CHRM2CACNA1IKCNH2CHRM3 | |
| SCHEMBL26430739 | 0.95 | CHRM1 (0.55) | CHRM1CHRM2CACNA1IKCNH2CHRM3 | |
| SCHEMBL23744510 | 0.92 | CHRM2 (0.64) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL23744422 | 0.92 | CHRM2 (0.64) | CHRM1CHRM2CHRM3CHRM5CHRM4 | |
| SCHEMBL23744641 | 0.87 | CHRM1 (0.54) | CHRM1CHRM2CACNA1IKCNH2CHRM3 | |
| SCHEMBL23744599 | 0.87 | CHRM1 (0.54) | CHRM1CHRM2CACNA1IKCNH2CHRM3 | |
| SCHEMBL26090366 | 0.87 | CHRM1 (0.51) | CHRM1CHRM2CACNA1IKCNH2CHRM3 | |
| SCHEMBL26086720 | 0.87 | CHRM1 (0.51) | CHRM1CHRM2CACNA1IKCNH2CHRM3 | |
| SCHEMBL23744454 | 0.84 | CHRM2 (0.62) | CHRM1CHRM2CACNA1IKCNH2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |